Literature DB >> 3435696

Polymorphism of dextromethorphan oxidation in a French population.

D Larrey1, G Amouyal, M Tinel, P Letteron, A Berson, G Labbe, D Pessayre.   

Abstract

Genetically-controlled drug oxidation capacity was studied using dextromethorphan, an anti-tussive drug, as the test compound in 103 healthy white French subjects (61 males and 42 females). Phenotyping was performed using the metabolic ratio (MR) calculated as MR = 0-10 h urinary output of dextromethorphan/0-10 h urinary output of dextrorphan, after oral administration of 40 mg (113.6 mumol) of dextromethorphan hydrobromide. The log MR was bimodally distributed: 99 subjects (96.1%) were phenotyped as extensive metabolizers; they had a log MR between -3.1 and -1.1, a urinary output of dextromethorphan below 5 mumol 10 h-1 and a urinary output of dextrorphan above 20 mumol 10 h-1. Four subjects (3.9%) were phenotyped as poor metabolizers; they had a log MR between -0.5 and +0.7, a urinary output of dextromethorphan above 5 mumol 10 h-1 and a urinary out of dextrorphan below 20 mumol 10 h-1.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3435696      PMCID: PMC1386343          DOI: 10.1111/j.1365-2125.1987.tb03230.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism.

Authors:  A Küpfer; B Schmid; R Preisig; G Pfaff
Journal:  Lancet       Date:  1984-09-01       Impact factor: 79.321

Review 2.  Inherited defects of hepatic drug metabolism.

Authors:  A Küpfer; R Preisig
Journal:  Semin Liver Dis       Date:  1983-11       Impact factor: 6.115

3.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

4.  Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism.

Authors:  D Larrey; L M Distlerath; G A Dannan; G R Wilkinson; F P Guengerich
Journal:  Biochemistry       Date:  1984-06-05       Impact factor: 3.162

5.  Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism.

Authors:  L M Distlerath; P E Reilly; M V Martin; G G Davis; G R Wilkinson; F P Guengerich
Journal:  J Biol Chem       Date:  1985-07-25       Impact factor: 5.157

6.  Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation.

Authors:  B Schmid; J Bircher; R Preisig; A Küpfer
Journal:  Clin Pharmacol Ther       Date:  1985-12       Impact factor: 6.875

7.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

  7 in total
  15 in total

1.  Development of an ELISA to study the polymorphism of dextromethorphan oxidation in a French population.

Authors:  J P Frèche; S Dragacci; A M Petit; J P Siest; M M Galteau; G Siest
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Effect of liver disease on dextromethorphan oxidation capacity and phenotype: a study in 107 patients.

Authors:  D Larrey; G Babany; M Tinel; E Freneaux; G Amouyal; F Habersetzer; P Letteron; D Pessayre
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

3.  Dextromethorphan: polymorphic serum pattern of the O-demethylated and didemethylated metabolites in man.

Authors:  O Mortimer; B Lindström; H Laurell; U Bergman; A Rane
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

4.  Extensive oxidative metabolism of dextromethorphan in patients with almitrine neuropathy.

Authors:  L Belec; D Larrey; H De Cremoux; M Tinel; F Louarn; D Pessayre; R Gherardi
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

5.  Phenotyping polymorphic drug metabolism in the French Caucasian population.

Authors:  E Jacqz; H Dulac; H Mathieu
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Pharmacokinetics of sabeluzole and dextromethorphan oxidation capacity in patients with severe hepatic dysfunction and healthy volunteers.

Authors:  G P Pageaux; J Micallef; M B Nataf; J C Levron; B Lacarelle; J P Le Moing; P Bouhours; O Blin
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

7.  Dextromethorphan O-demethylation polymorphism in Jordanians.

Authors:  Y M Irshaid; H F al-Hadidi; N M Rawashdeh
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer.

Authors:  J C Duche; C Joanne; J Barre; H de Cremoux; J C Dalphin; A Depierre; P Brochard; J P Tillement; P Bechtel
Journal:  Br J Clin Pharmacol       Date:  1991-05       Impact factor: 4.335

9.  Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.

Authors:  D Wu; S V Otton; B A Sproule; U Busto; T Inaba; W Kalow; E M Sellers
Journal:  Br J Clin Pharmacol       Date:  1993-01       Impact factor: 4.335

10.  The effect of inhaled and oral dextromethorphan on citric acid induced cough in man.

Authors:  T J Grattan; A E Marshall; K S Higgins; A H Morice
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.